LYRA
$7.84
Lyra Therapeutics
($.10)
(1.26%)
LYRA
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.71)
Revenue:  $0.00 Mil
Tuesday
Nov 9
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when LYRA reports earnings?
Beat
Meet
Miss

Where is LYRA's stock price going from here?
Up
Flat
Down
Stock chart of LYRA
Analysts
Summary of analysts' recommendations for LYRA
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and consistently deliver medicines directly to the affected tissue. Its initial product candidates consist LYR-210 and LYR-220 which are in clinical stage. Lyra Therapeutics Inc. is based in Watertown, Mass.